A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called ABBV-903 to see if it is safe and well-tolerated by healthy adults. Researchers want to know how the drug behaves in the body when taken in different doses.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy volunteers, it might be expected that participants are not on any regular medications.
What data supports the effectiveness of the drug ABBV-903?
The research indicates that treatments targeting CD33, like ABBV-903, have shown effectiveness in eliminating acute myeloid leukemia cells by engaging the immune system to attack cancer cells. Similar treatments have demonstrated strong anti-leukemic effects in laboratory settings, suggesting potential effectiveness for ABBV-903.12345
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive single and multiple ascending doses of ABBV-903 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABBV-903
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois